Avista Capital Partners

The firm was founded in 2005 by Steven Webster, Thompson Dean and David Burgstahler, as a spinoff from Credit Suisse's private equity arm DLJ Merchant Banking Partners (Dean was head of DLJMBP).{{cite web|url=https://www.wsj.com/articles/avista-capital-plans-to-launch-blank-check-company-for-health-care-deals-1472830830|title=Avista Capital Plans to Launch Blank-Check Company for Health-Care Deals|last=Farrell|first=Maureen|work=The Wall Street Journal|date=September 2, 2016|access-date=September 13, 2018}} AltAssets, June 14, 2007 Avista's spinoff from Credit Suisse was at the same time as private equity groups from other leading investment banks were formed including JPMorgan Chase's CCMP Capital, Citigroup's Court Square Capital Partners, Deutsche Bank's MidOcean Partners, and Morgan Stanley's Metalmark Capital.

In 2007, the firm closed its first fund at $2 billion.[http://www.altassets.com/news/arc/2007/nz11084.php Avista closes $2bn fund] {{webarchive |url=https://web.archive.org/web/20081202081617/http://www.altassets.com/news/arc/2007/nz11084.php |date=December 2, 2008 }}. AltAssets, June 14, 2007{{cite web|last1=Moore|first1=Heidi|title=Avista fund challenges Credit Suisse|url=https://www.fnlondon.com/articles/avista-fund-challenges-credit-suisse-1-20070614|website=www.fnlondon.com|accessdate=September 13, 2018|location=New York|date=14 June 2007}} This included a commitment from predecessor Credit Suisse, whereas fellow spin-off Diamond Castle did not.{{cite web|title=Avista, With CS Backing, Makes Splashy Debut|url=https://www.pehub.com/buyouts/avista-with-cs-backing-makes-splashy-debut/|website=PE Hub|accessdate=September 13, 2018|date=25 June 2007}} Avista’s second fund closed with $1.8 billion of commitments, which was lower than its original target between $2.5 and $3 billion. The firm cited changes in North American alternative investment strategies for its lower target.{{cite web|last1=Griffith|first1=Erin|title=Better Late Than Never: Avista Closes Second Fund - PE Hub|url=https://www.pehub.com/2010/03/avista-closes-fund-at-18-billion/|website=PE Hub|accessdate=September 13, 2018|date=16 March 2010}}

Its third fund closed in 2013 with $1.4 billion in commitments and in 2016 Avista began raising its fourth fund with UBS acting as the placement agent. The fourth fund does not include an energy component and is focused exclusively on healthcare.Dan Primack, [http://fortune.com/2015/12/02/avista-capital-makes-major-change-to-fund-strategy/ "Avista Capital Makes Major Change to Fund Strategy,"] Fortune, December 2, 2015.Luisa Beltran, [https://www.pehub.com/buyouts/avista-capital-seeks-750-mln-to-1-bln-for-fund-iv-sources/ "Avista Capital seeks $750 mln to $1 bln for Fund IV: sources,"] [https://www.pehub.com/ PE Hub], October 20, 2016. Fund IV closed in 2017 with $775 million of committed capital.{{cite web|url=https://www.altassets.net/private-equity-news/by-news-type/deal-news/avista-capital-partners-follows-1-2bn-fund-v-close-with-emolecules-buyout.html|title=EXCLUSIVE: Avista Capital Partners' eMolecules buyout values company at about $250m|work=AltAssets|date=March 25, 2021}} The former Avista energy team spun-out and formed an independent firm AEC Partners in 2017 and began raising their first fund in 2017. In 2021, Avista closed its fifth fund after raising $1.2 billion in capital, above the original target of $775 million.{{Cite web|last=Falconer|first=Kirk|title=Avista wins healthcare bet with close of Fund V at $1.2bn hard-cap|url=https://www.buyoutsinsider.com/avista-wins-healthcare-bet-with-close-of-fund-v-at-1-2bn-hard-cap/|access-date=2021-09-23|website=Buyouts|date=2 March 2021 |language=en}}

In 2007, Avista acquired Bristol-Myers Squibb Co.'s medical imaging unit for $525 million. The company, later renamed Lantheus, went public in 2015.[https://www.wsj.com/articles/avista-selling-shares-of-lantheus-in-secondary-offering-1489520007 “Avista Selling Shares of Lantheus in Secondary Offering,”] The Wall Street Journal, March 14, 2017.

In 2008, Avista, together with Nordic Capital Fund VII, bought ConvaTec, a wound and ostomy care business, from Bristol-Myers Squibb for $4.1 billion. ConvaTec went public on the London Stock Exchange in 2016 and, in 2017, both funds sold approximately 20% of the company to Danish fund Novo.Bill Berkrot and Ransdell Pierson, [https://www.reuters.com/article/us-bristolmyers-nordic/bristol-myers-to-sell-convatec-unit-for-4-1-bln-idUSN0230052120080502 "Bristol-Myers to sell ConvaTec unit for $4.1 bln"], Reuters, May 2, 2008.[https://www.wsj.com/articles/nordic-capital-avista-reduce-holding-in-convatec-1490811005 "Nordic Capital, Avista Reduce Holding in ConvaTec,"] The Wall Street Journal, March 29, 2017.

In 2009, one of Avista's media acquisitions, the Minneapolis Star Tribune newspaper, the nation's 15th-largest daily paper, filed for Chapter 11 bankruptcy.{{cite news|author=Steller, Chris |title=A cold day indeed for Minnesota: It's bankruptcy for the Star Tribune |url=http://minnesotaindependent.com/23495/a-cold-day-indeed-for-minnesota-its-bankruptcy-for-the-star-tribune |date=January 15, 2009 |publisher=The Minnesota Independent |accessdate=2009-01-15 |url-status=dead |archiveurl=https://web.archive.org/web/20090119071449/http://minnesotaindependent.com/23495/a-cold-day-indeed-for-minnesota-its-bankruptcy-for-the-star-tribune |archivedate=2009-01-19 }}{{cite news|author=Schmickle, Sharon|title=Strib files for bankruptcy and lists unsecured creditors|url=http://www.minnpost.com/stories/2009/01/15/5909/star_tribune_files_for_bankruptcy_and_lists_unsecured_creditors|date=January 15, 2009|publisher=MinnPost|accessdate=2009-01-15|archive-url=https://web.archive.org/web/20090121180710/http://www.minnpost.com/stories/2009/01/15/5909/star_tribune_files_for_bankruptcy_and_lists_unsecured_creditors|archive-date=January 21, 2009|url-status=dead}}

In 2010, Avista, together with Ontario Teachers’ Pension Plan, purchased INC Research, a contract research organization, and later took the company public in 2012. Avista exited its position in 2016.{{cite news |last1=Akinnibi |first1=Fola |title=PE-Backed Inc Research Unveils $204M Secondary Share Sale |url=https://www.law360.com/articles/829511/pe-backed-inc-research-unveils-204m-secondary-share-sale |accessdate=21 September 2018 |publisher=Law360 |date=17 August 2016}} Together with DLJ Merchant Banking Partners, Nordic Capital and Coller Capital, Avista sold Swiss drug-maker Nycomed for €9.6 billion in cash to Takeda Pharmaceutical Corp. in 2011.{{cite news |last1=Primack |first1=Dan |title=M&A Deals |url=http://fortune.com/2011/05/19/ma-deals-2/ |accessdate=21 September 2018 |publisher=Fortune |date=19 May 2011}} Also in 2011, Avista acquired DataBank Ltd., an enterprise-class managed data center based in Dallas, Texas, and sold the company to Digital Bridge Holdings LLC in 2016.{{cite web|url=https://www.reuters.com/article/us-databank-m-a-digital-bridge/digital-bridge-acquires-data-center-company-idUSKCN0ZU17F|title=Digital Bridge acquires data center company|last=Baker|first=Liana|publisher=Reuters|date=July 14, 2016|access-date=December 4, 2017}} Also in 2010, Avista invested in specialty pharmaceutical company OptiNose Inc. Avista took the company public in 2015.Armie Margaret Lee, [https://www.thestreet.com/story/14366935/1/optinose-drug-and-2018.html "OptiNose Gears Up for a Big Year,"] TheStreet.com, October 30, 2017.

In 2012, Avista, together with Partners Group, purchased Strategic Partners, a manufacturer and marketer of uniforms and footwear to support healthcare professionals, schools, and parents. In 2016, Avista sold the company to New Mountain Capital.{{cite news |last1=Dorbian |first1=Iris |title=Partners Group and Avista to exit medical scrubs provider Strategic Partners |url=https://www.pehub.com/2016/07/3342070/ |accessdate=22 September 2018 |publisher=PE Hub |date=6 July 2016}}

In 2013, Avista acquired a controlling stake in Vertical/Trigen Holdings for an undisclosed price and, in 2015, the company joined forces with Osmotica Pharmaceutical, a specialty pharmaceutical and generics company.Braden Kelner, [https://www.wsj.com/articles/DJFLBO0120151204ebc4l8vun "Avista-Backed Vertical/Trigen to Merge With Osmotica,"] The Wall Street Journal, December 4, 2015. Also in 2013, Avista acquired Zest Dental Solutions, a maker of dental products, from the Jordan Company and, in 2018, Avista sold Zest to BC Partners for an undisclosed amount.[https://www.penews.com/articles/bc-partners-buys-u-s-dentistry-products-maker-20180209 "BC Partners Buys U.S. Dentistry Products Maker,"] Private Equity News, February 9, 2018.

In 2016, Avista acquired the contract research organization MPI Research, a provider of testing services for biopharmaceutical and medical devices. Avista sold the company to Charles River Laboratories for approximately $800 million in cash in 2018.{{cite news |last1=Dorbian |first1=Iris |title=PE-backed Charles River to buy MPI Research for about $800 mln |url=https://www.pehub.com/2018/02/pe-backed-charles-river-buy-mpi-research-800-mln/ |accessdate=22 September 2018 |publisher=PE Hub |date=14 February 2018}} In 2017, Avista acquired Express Scripts’ United BioSource division and National Spine & Pain Centers (NSPC) from Sentinel Capital Partners, both for undisclosed sums.{{cite news |title=Avista to Buy Express Scripts Subsidiary |url=https://www.wsj.com/articles/avista-to-buy-express-scripts-subsidiary-1511815115 |accessdate=21 September 2018 |work=The Wall Street Journal |date=27 November 2017}} Also in 2017, Avista acquired Miraca Life Sciences, a subsidiary of Japanese clinical diagnostics and laboratory testing company Miraca Holdings Inc.[https://www.wsj.com/articles/avista-to-buy-miraca-life-sciences-1506097969 "Avista to Buy Miraca Life Sciences,"] The Wall Street Journal, September 22, 2017

In November 2017, Express Scripts announced it was divesting United BioSource Corp. (UBC), its pharmaceutical support business. UBC was sold to Avista Capital Partners.

In 2018, Avista contributed to a $110 million round of financing for Braeburn Pharmaceuticals.Matthew Guarnaccia, [https://www.law360.com/articles/1001178/opioid-addiction-treatment-co-nabs-110m-for-new-product "Opioid Addiction Treatment Co. Nabs $110M For New Product,"] Law360, January 11, 2018. Also in 2018, Avista, together with Dana Holdings, purchased Kramer Laboratories, an over-the-counter healthcare platform. A month later, Kramer Laboratories acquired Nizoral, an anti-dandruff shampoo brand, from Janssen Pharmaceutical NV, part of Johnson & Johnson.Laura Cooper, [https://www.wsj.com/articles/kramer-laboratories-acquires-dandruff-shampoo-brand-1529928497 “Kramer Laboratories Acquires Dandruff Shampoo Brand,”] The Wall Street Journal, June 25, 2018. Kramer changed its name to Arcadia in 2019 and went on to acquire Naturelo and the US rights to Kaopectate, both in 2020. In August 2021, Avista sold Arcadia to Bansk Group for a return of approximately 3.7 times its investment.Sarah Pringle, [https://www.pehub.com/avista-to-make-3-7-times-its-money-with-sale-of-arcadia-consumer-healthcare/ "Avista to Make 3.7 Times its Money with Sale of Arcadia Consumer Healthcare,"] PE Hub, August 9, 2021.

In December 2018, Avista Healthcare Public Acquisition Corp. (AHPAC) acquired regenerative medicine specialist Organogenesis. As part of the deal, Organogenesis became a wholly owned subsidiary of AHPAC, while Avista invested $92 million in the combined company.{{cite web|url=https://www.massdevice.com/shareholders-approve-avista-organogensis-tie-up/|title=Shareholders approve Avista, Organogenesis tie up|first=Fink|last=Densford|work=Mass Device|date=December 11, 2018}}

In September 2019, Avista acquired California-based medtech component manufacturer GCM Holding Corp. from May River Capital for an undisclosed amount.Cromwell Schubarth, [https://www.bizjournals.com/sanjose/news/2019/09/04/the-funded-over-1b-in-new-funding-deals-and-5-ipo.html "The Funded: Over $1B in new funding deals and 5 IPO filings in Bay Area this week,"] Silicon Valley Business Journal, September 4, 2019. Also in 2019, Avista sold Trimb Healthcare, an over-the-counter health-care product business, to Karo Pharma.Laura Cooper, [https://www.wsj.com/articles/avista-capital-backs-consumer-health-care-company-in-336-million-deal-11590791786 "Avista Capital Backs Consumer Health-Care Company in $336 Million Deal,"] The Wall Street Journal, May 31, 2020.

In January 2021, Avista acquired Solmetex Inc., a provider of waste compliance products, including amalgam separators, for the American and Canadian dental industries.{{cite web|url=https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/avista-capital-acquires-dental-waste-management-product-company-solmetex-62180367|title=Avista Capital acquires dental waste management product company Solmetex|first= Abdul Rehman|last=Maqbool|work=S&P Global|date=January 19, 2021}} In March 2021, Avista Capital Partners agreed to buy chemical and bioreagent specialist eMolecules for $250 million.

• DLJ Merchant Banking Partners

{{reflist|2}}

{{refbegin}}

{{refend}}

• [http://www.avistacap.com Avista Capital Partners] (company website)

{{private equity firms}}

{{Merchant banking private equity groups}}

{{Credit Suisse}}

Category:Private equity firms of the United States

Category:Financial services companies established in 2005

Category:Hedge fund firms in New York City